Mereo BioPharma Group plc (AIM:MPH)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 26.50
-0.50 (-1.85%)
Inactive · Last trade price on Dec 17, 2020
Mereo BioPharma Group Revenue
In the year 2025, Mereo BioPharma Group had annual revenue of $500.00K USD.
Revenue
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$12.82K
Employees
39
Market Cap
45.84M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 500.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Mereo BioPharma Group News
- 2 months ago - JPMorgan Downgrades Mereo BioPharma (MREO) Amid Regulatory Concerns, Highlighting Valuation and ... - GuruFocus
- 2 months ago - JPMorgan downgrades Mereo to Underweight on regulatory uncertainty - TheFly
- 2 months ago - Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan - TheFly
- 2 months ago - Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 - Nasdaq
- 2 months ago - Mereo BioPharma Group Releases Q2 2026 Financial Results - AlphaStreet
- 2 months ago - Mereo BioPharma (MREO) Advances Alvelestat Program, Faces Valuation Challenges - GuruFocus
- 2 months ago - Mereo BioPharma (MREO) Licenses Alvelestat Rights to Sentynl Therapeutics Amid High Valuation ... - GuruFocus
- 2 months ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq